TY - JOUR
T1 - Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
AU - AUTHOR GROUP
AU - Heneghan, Carl
AU - Ward, Alison
AU - Perera, Rafael
AU - Bankhead, Clare
AU - Fuller, Alice
AU - Stevens, Richard
AU - Bradford, Kairen
AU - Tyndel, Sally
AU - Alonso-Coello, Pablo
AU - Ansell, Jack
AU - Beyth, Rebecca
AU - Bernardo, Artur
AU - Christensen, Thomas Decker
AU - Cromheecke, M. E.
AU - Edson, Robert G.
AU - Fitzmaurice, David
AU - Gadisseur, Alain P. A.
AU - Garcia-Alamino, Josep M.
AU - Gardiner, Chris
AU - Hasenkam, J. Michael
AU - Jacobson, Alan
AU - Kaatz, Scott
AU - Kamali, Farhad
AU - Khan, Tayyaba Irfan
AU - Knight, Eve
AU - Körtke, Heinrich
AU - Levi, Marcel
AU - Matchar, David
AU - Menéndez-Jándula, Bárbara
AU - Rakovac, Ivo
AU - Schaefer, Christian
AU - Siebenhofer, Andrea
AU - Souto, Juan Carlos
AU - Sunderji, Rubina
AU - Gin, Kenneth
AU - Shalansky, Karen
AU - Völler, Heinz
AU - Wagner, Otto
AU - Zittermann, Armin
PY - 2012
Y1 - 2012
N2 - Background Uptake of self-testing and self-management of oral coagulation has remained inconsistent, despite good evidence of their effectiveness. To clarify the value of self-monitoring of oral anticoagulation, we did a meta-analysis of individual patient data addressing several important gaps in the evidence, including an estimate of the effect on time to death, first major haemorrhage, and thromboembolism. Methods We searched Ovid versions of Embase (1980-2009) and Medline (1966-2009), limiting searches to randomised trials with a maximally sensitive strategy. We approached all authors of included trials and requested individual patient data: primary outcomes were time to death, first major haemorrhage, and first thromboembolic event. We did prespecified subgroup analyses according to age, type of control-group care (anticoagulation-clinic care vs primary care), self-testing alone versus self-management, and sex. We analysed patients with mechanical heart valves or atrial fibrillation separately. We used a random-effect model method to calculate pooled hazard ratios and did tests for interaction and heterogeneity, and calculated a time-specific number needed to treat. Findings Of 1357 abstracts, we included 11 trials with data for 6417 participants and 12 800 person-years of follow-up. We reported a significant reduction in thromboembolic events in the self-monitoring group (hazard ratio 0.51; 95% CI 0.31-0.85) but not for major haemorrhagic events (0.88, 0.74-1.06) or death (0.82, 0.62-1.09). Participants younger than 55 years showed a striking reduction in thrombotic events (hazard ratio 0.33, 95% CI 0.17-0.66), as did participants with mechanical heart valve (0.52, 0.35-0.77). Analysis of major outcomes in the very elderly (age >= 85 years, n=99) showed no significant adverse effects of the intervention for all outcomes. Interpretation Our analysis showed that self-monitoring and self-management of oral coagulation is a safe option for suitable patients of all ages. Patients should also be offered the option to self-manage their disease with suitable health-care support as back-up
AB - Background Uptake of self-testing and self-management of oral coagulation has remained inconsistent, despite good evidence of their effectiveness. To clarify the value of self-monitoring of oral anticoagulation, we did a meta-analysis of individual patient data addressing several important gaps in the evidence, including an estimate of the effect on time to death, first major haemorrhage, and thromboembolism. Methods We searched Ovid versions of Embase (1980-2009) and Medline (1966-2009), limiting searches to randomised trials with a maximally sensitive strategy. We approached all authors of included trials and requested individual patient data: primary outcomes were time to death, first major haemorrhage, and first thromboembolic event. We did prespecified subgroup analyses according to age, type of control-group care (anticoagulation-clinic care vs primary care), self-testing alone versus self-management, and sex. We analysed patients with mechanical heart valves or atrial fibrillation separately. We used a random-effect model method to calculate pooled hazard ratios and did tests for interaction and heterogeneity, and calculated a time-specific number needed to treat. Findings Of 1357 abstracts, we included 11 trials with data for 6417 participants and 12 800 person-years of follow-up. We reported a significant reduction in thromboembolic events in the self-monitoring group (hazard ratio 0.51; 95% CI 0.31-0.85) but not for major haemorrhagic events (0.88, 0.74-1.06) or death (0.82, 0.62-1.09). Participants younger than 55 years showed a striking reduction in thrombotic events (hazard ratio 0.33, 95% CI 0.17-0.66), as did participants with mechanical heart valve (0.52, 0.35-0.77). Analysis of major outcomes in the very elderly (age >= 85 years, n=99) showed no significant adverse effects of the intervention for all outcomes. Interpretation Our analysis showed that self-monitoring and self-management of oral coagulation is a safe option for suitable patients of all ages. Patients should also be offered the option to self-manage their disease with suitable health-care support as back-up
U2 - 10.1016/S0140-6736(11)61294-4
DO - 10.1016/S0140-6736(11)61294-4
M3 - Article
C2 - 22137798
SN - 0140-6736
VL - 379
SP - 322
EP - 334
JO - Lancet
JF - Lancet
IS - 9813
ER -